Presentation Archives - Page 4 of 9

Phosphatidylinositol Kinases: Structural Biology Services

Within the phosphatidylinositol 3-kinase (PI3K) family, the heterodimer comprising the p110-α catalytic and p85-α regulatory subunits (encoded by PIK3CA and...

Janus Kinases: Structural Biology Services

The inhibition of the JAK/STAT signaling pathway is a promising approach for the treatment of cancers and inflammatory diseases. To...

CRBN Structural Biology Services

Targeted protein degradation of disease-causing proteins by the E3 ligase cereblon (CRBN) represents a new therapeutic strategy for addressing challenging-to-treat...

WRN Helicase: Structural Biology Services

Inhibition of the Werner syndrome RecQ helicase (WRN) is a promising approach for the treatment of cancers commonly associated with...

Clinical Drug Resistant PDX Models

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. The development of targeted therapies...

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...

Paclitaxel-Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...